

# Northwestern University Feinberg School of Medicine IMMUNIZATION FORM VISITING STUDENT ELECTIVE PROGRAM

### **Immunization Form Instructions:**

All visiting medical students must submit a completed (AAMC) Association of American Medical Colleges Immunization Form that has been typewritten and signed by their healthcare provider.

- All 4 pages of the AAMC Immunization Form must be completed and include supporting health vaccination, Hepatitis B Surface Antibody lab titer report and test result documentation.
- The latest Td/Tdap vaccine must be less than 10 years old at start of clerkship.
- TB Test result and Influenza vaccine results should be up-to date in accordance with our health facility policy for health clearance approval:
  - Domestic Students Influenza vaccine completed annually during each flu season. TB Test result cannot be older than 12 months prior to clerkship start date.
  - ➤ Global Partner (International) Students Only Influenza vaccine completed annually during each flu season and a TB QuantiFERON Gold Blood Test completed only in the United States within the past 6 months prior to clerkship start. If accepted for clerkship, international students can schedule appointment to receive TB testing and other vaccinations needed at Northwestern Student Health.
- No other immunization form may be substituted.
- All health documents must be transcribed in ENGLISH.

#### Where to Submit Form:

- Domestic Students submit via VSAS portal
- International Students submit via email to Visting Student Clerkship Coordinator

\*\*Failure to follow all instructions will result in an incomplete application.\*\*



Last Name:	Firs	rst Name: Middle Initial:
DOB:	Street A	Address:
Medical School:		City:
Cell Phone:		State:
Primary Email:	Z	ZIP Code:
Student ID:		

MMR (Measles, Mumps, Rubella) – 2 doses of MMR vaccine or two (2) doses of Measles, two (2) doses of Mumps and (1) dose of Rubella; or serologic proof of immunity for Measles, Mumps and/or Rubella. Choose only one option.						
Option 1	Option 1 Vaccine Date					
MMR -2 doses of MMR	MMR Dose #1					
vaccine	MMR Dose #2					
Option 2	Vaccine or Test	Date				
Measles	Measles Vaccine Dose #1		Serology Results			
-2 doses of vaccine or positive serology	Measles Vaccine Dose #2		Qualitative Titer Results:	☐ Positive ☐ Negative		
positive serology	Serologic Immunity (IgG antibody titer)		Quantitative Titer Results:	IU/ml		
	Mumps Vaccine Dose #1		Serology Results			
Mumps -2 doses of vaccine or positive serology	Mumps Vaccine Dose #2		Qualitative Titer Results:	☐ Positive ☐ Negative		
positive serology	Serologic Immunity (IgG antibody titer)		Quantitative Titer Results:	IU/ml		
			Serology Results			
Rubella -1 dose of vaccine or	Rubella Vaccine		Qualitative Titer Results:	☐ Positive ☐ Negative		
positive serology	Serologic Immunity (IgG antibody titer)		Quantitative Titer Results:	IU/ml		
Tetanus-diphtheria-pert	tussis – One (1) dose of adult Tdap. If last Tdap is mo	ore than 10 years old, pro	ovide dates	of last Td and Tdap		
	Tdap Vaccine (Adacel, Boostrix, etc)					
	Td Vaccine (if more than 10 years since last Tdap)					
Varicella (Chicken Pox) - 2 doses of vaccine or positive serology						
	Varicella Vaccine #1		Serology Results			
	Varicella Vaccine #2		Qualitative Titer Results:	☐ Positive ☐ Negative		
	Serologic Immunity (IgG antibody titer)		Quantitative Titer Results:	IU/ml		
Influenza Vaccine - 1 dose annually each fall						
Date of last dose		Date				
0. /20. 2300	Flu Vaccine					



ame:			Date of Birth:			
(La	ast, First, Middle Initial)		(mm/dd/yyyy)			
<b>QUANTITATIVE</b> Hepatitis B Statest result is negative, repeat a	n - 3 doses of Engergix-B, Recombivax or Twinrix va urface Antibody test drawn 4-8 weeks after last vaccir nother Hepatitis B vaccine series followed by a repea a "non-responder" status is assigned. See: http://ww	ne dose. A test titer <u>&gt;</u> 10 t test titer.If the Hepatiti	mIU/mL is positive for i s B Surface Antibody to	mmunity. If the est is negative	Copy Attached	
	3-dose vaccines (Energix-B, Recombivax, Twinrix) 2-dose vaccines (Heplisav-B)	3 Dose Series	2 Dose Series			
Primary Hepatitis B Series	Hepatitis B Vaccine Dose #1					
Heplisav-B only requires two	Hepatitis B Vaccine Dose #2					
doses of vaccine followed by antibody testing	Hepatitis B Vaccine Dose #3					
	QUANTITATIVE Hep B Surface Antibody Test		mIU/ml			
Repeat		3 Dose Series	2 Dose Series			
Hepatitis B Series	Hepatitis B Vaccine Dose #4					
Only If no response to primary series	Hepatitis B Vaccine Dose #5					
Heplisav-B only requires two doses of vaccine followed by	Hepatitis B Vaccine Dose #6					
antibody testing	QUANTITATIVE Hep B Surface Antibody Test		mIU/ml			
Hepatitis B Vaccine Non-responder  If the Hepatitis B Surface Antibody test is negative (titer less than 10 mIU/mL) after a primary and repeat vaccine series, vaccine non-responders should be counseled and evaluated appropriately. Certain institutions may request signing an "acknowledgement of non-responder status" document before clinical placements.				seled and		
	Additional Document	ation				
include meningitis vaccine	ve additional requirements depending upon rot which is mandated in some states if you live in you may also be required to provide proof of v	dormitory style hous	ing. If you will be pa			
Vaccination, Test or E	Date	Result or Inte	rpretation			
Physical Exam (if requir						



Name:		Date of Birth:	
	(Last, First, Middle Initial)		(mm/dd/yyyy)

**TUBERCULOSIS (TB) SCREENING** – All U.S. healthcare personnel are screened pre-placement for TB. Results of the last (2) TB Skin Tests (TSTs)) or (1) IGRA blood test are required <u>regardless</u> of prior BCG status. The 2-step TST protocol must have been placed within the past 12 months prior to clinical duties, and must have been performed in the U.S. The second TST must be placed at least 1 week after the first TST read date. If you have a history of a positive TST (PPD)≥10mm or a positive IGRA blood test, please supply information regarding any evaluation and/or treatment below. You only need to complete ONE section, A or B.

Skin test or IGRA results should not expire during proposed elective rotation dates

or

must be updated with the receiving institution prior to rotation.

Tuberculosis Screening History						
	Section A		Date Placed	Date Read	Result	Interpretation
		TST #1			mm	☐ Pos ☐ Neg ☐ Equiv
>		TST #2			mm	□ Pos □ Neg □ Equiv
stor	History of Negative TB Skin					
on your history	Test or Blood Test			Date	Result	
ō				Date	Resuit	
l ď	T-spots or QuantiFERON TB Gold blood tests for tuberculosis	QuantiFERON TB (Interferon Gamma Relea	sing Assay)		☐ Positive ☐ Neg	gative 🔲 Indeterminate
	Use additional rows as needed	QuantiFERON TB (Interferon Gamma Relea	Gold or T-Spot sing Assay)		☐ Positive ☐ Neg	gative 🔲 Indeterminate
section based						
on			1		1	
당	Section B		Date Placed	Date Read	Result	
		Positive TST			mm	
1B	History of			Date	Result	
_		QuantiFERON TB (Interferon Gamma Relea	Gold or T-Spot sing Assay)		□ Positive □ Ne	egative 🚨 Indeterminate
y o	Positive Skin Test or	Chest X-ray*			*Provide documer	ntation or result
ou	Positive Blood Test	Treated for latent TB infection (LTBI)?			☐ Yes ☐ No	
complete only one						
Juc						
e C		Date of Last Annual TB Symptom Questionnaire				
Please						
<u> </u>						



ame:	(Last, First, Middle Initial)	Date of Birth:	(mm/dd/yyyy)
	Additional	Information	
	MUST BE SIGNED BY A LICENSED H	EALTHCARE PROFESSION	ONAL OR DESIGNEE:

Healthcare Professional Signature:		Date:
Printed Name:		Office Use Only
Title:		Office Ose Offiy
Address Line 1:		
Address Line 2:		
City:		
State:		
Zip:		
Phone:	() Ext:	
Fax:	()	
Email Contact:		

#### \*Sources:

- 1. Hepatitis B In: Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Hamborsky J, Kroger A, Wolfe S, eds. 13th ed. Washington D.C. Public Health Foundation, 2015
- 2. Immunization of Health-Care Personnel: Recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR, Vol 60(7):1-45
- 3. CDC Guidance for Evaluating Health-Care Personnel for Hepatitis B Virus Protection and for Administering Postexposure Management, MMWR, Vol 62(RR10):1-19
- 4. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, MMWR Vol 67(1):1-31
- 5. Sosa LE, Nijie GL, Lobato MN, et.al. Tuberculosis Screening, Testing, and Treatment of U.S. Health Care Personnel: Recommendations from National Tuberculosis Controllers Association and CDC, 2019. MMWR2019;68:439-443. https://www.cdc.gov/mmwr/volumes/68/wr/mm6819a3.htm?s cid+mm6819a3 w